Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05683353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 11 months later Dec 2025 → Dec 2027
See other at-risk trials from Peking University First Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 2025 to Dec 2027
    • Eligibility criteria revised
    • Publications: details revised at 7 of 7 entries
    • Study description expanded, about 3 words
  2. Primary and study completion dates: Dec 2024 to Dec 2025v4
  3. Primary completion date: Jun 2023 to Dec 2024
    • Study completion date: Jul 2023 to Dec 2024
    v3
  4. Eligibility criteria shortened, about 28 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to compare the immune function and infection mechanism of patients with hematologic tumors and those people without underlying diseases after infection with SARS-CoV-2. Clinical characteristics, treatment options and responses will be collected. Peripheral blood will be collected from patients with hematologic tumors infected with SARS-CoV-2 and those people without underlying diseases infected with SARS-CoV-2.
Trial Details
NCT Number NCT05683353
Lead Sponsor Peking University First Hospital
Conditions
(from sponsor)		 SARS-CoV-2 Infection, Hematologic Malignancy
Related terms COVID-19, Hematologic Neoplasms, Leukemia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov